NCT02713672View on ClinicalTrials.gov

Cost-effectiveness of CYP2D6 and CYP2C19 Genotyping in Psychiatric Patients in Curacao

NACompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
CYP2D6, Psychiatric Patients
Interventions
OTHER

Dose adjustment according to genotype

Patients in the intervention group received a dose adjustment according to their CYP2D6 or CYP2C19 genotype based on guidelines of the KNMP

Trial Locations (1)

3818EW

Zon en Schild, Amersfoort

Sponsors

Collaborators (1)

Parnassia
All Listed Sponsors
collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

collaborator

Parnassia

UNKNOWN

collaborator

Klinika Capriles

UNKNOWN

collaborator

Psychiaters Maatschap Antillen

UNKNOWN

lead

GGZ Centraal

OTHER

NCT02713672 - Cost-effectiveness of CYP2D6 and CYP2C19 Genotyping in Psychiatric Patients in Curacao | Biotech Hunter | Biotech Hunter